Question 1

What is the catalog number for HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued?

Accepted Answer

The catalog number for HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued is 036669-APC.

Question 2

What sizes are available for HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued?

Accepted Answer

HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued is available in the following size(s): 200 µL.

Question 3

Is HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued in stock?

Accepted Answer

HNRPAB, NT (HNRNPAB, ABBP1, HNRPAB, Heterogeneous nuclear ribonucleoprotein A/B, APOBEC1-binding protein 1) (APC) discontinued

Selected Variant

036669-APC

Size: 200 µL

Product Specifications

Clonality

Pab

Question 4

What is the shelf life of this product?

Accepted Answer

Shelf life and expiration dates vary by product and are shown on the product listing and label. Products used beyond their expiration date are not eligible for performance-related returns or refunds, so please check the lot number and expiry before use.

Question 5

What expression system was used for this recombinant protein?

Accepted Answer

The expression system, such as E. coli, HEK293, or insect cells, is listed on the datasheet under production details, which can affect post-translational modifications relevant to your application.

Question 6

Can I return this product if I ordered the wrong one?

Accepted Answer

As a consumer, you have a 14-day right of withdrawal from receipt under EU consumer protection law, submitted via our withdrawal/cancellation request form. Note this applies to unused, undamaged products, and doesn’t override the expiry/storage conditions on performance-based claims.